Resistance to human epidermal growth factor receptor type 2-targeted therapies.

Détails

ID Serval
serval:BIB_5F9ED99969DC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Resistance to human epidermal growth factor receptor type 2-targeted therapies.
Périodique
European Journal of Cancer
Auteur(s)
Thery J.C., Spano J.P., Azria D., Raymond E., Penault Llorca F.
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
50
Numéro
5
Pages
892-901
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
The overexpression of the human epidermal growth factor receptor type 2 (HER-2) is an independent prognostic factor of poor outcome in patients with breast cancer. Two compounds have been registered for HER-2-positive tumour treatment: trastuzumab, a humanised antibody directed against the HER-2 extracellular domain, and lapatinib, a small molecule acting as a dual EGF-R and HER-2 tyrosine kinase inhibitor. Although both drugs improve progression-free survival, many patients' tumours will exhibit primary resistance, or develop secondary resistance, to anti-HER-2 therapies. The recent significant improvement of survival gained with pertuzumab (an antibody disrupting dimerisation of the receptor) or trastuzumab emtansine (T-DM1, a cytotoxic drug vectored by trastuzumab binding) opened the way for new registrations. This review describes the molecular mechanisms by which tumour cells may adapt to and evade HER-2 inhibition by HER-2-targeted therapies and discusses strategies to prevent and overcome resistance to trastuzumab and lapatinib. These strategies may include the establishment of predictive markers, exploration of combination therapies and modulation of nodal targets.
Mots-clé
Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Agents/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Disease-Free Survival, Drug Resistance, Neoplasm/drug effects, Female, Humans, Maytansine/analogs & derivatives, Maytansine/therapeutic use, Receptor, ErbB-2/antagonists & inhibitors, Receptor, ErbB-2/metabolism
Pubmed
Création de la notice
11/02/2015 13:10
Dernière modification de la notice
20/08/2019 15:17
Données d'usage